Breast Cancer Resistance: Genetic Markers Predict CDK4/6 Inhibitor Failure

A novel study from Memorial Sloan Kettering Cancer Center (MSK) is shedding light on how interacting genetic mutations can shield breast cancer cells from the effects of CDK4/6 inhibitors, a common frontline treatment for metastatic hormone receptor-positive (HR+), HER2-negative breast cancer. Published in Nature, the research identifies specific genetic markers that may predict which patients are likely to develop resistance to these drugs, opening the door to more personalized treatment strategies.

Predicting Resistance Before Treatment Begins

CDK4/6 inhibitors have significantly improved outcomes for many patients with advanced breast cancer, but resistance inevitably develops in a substantial number of cases. Researchers have now discovered that a subset of patients – approximately 10 percent – experience resistance through the loss of a gene called RB1. Crucially, the MSK team found that certain pre-existing genetic characteristics can signal an increased risk of this resistance developing during treatment. These warning signs include:

• DNA repair deficiencies, particularly homologous recombination deficiency (HRD): HRD indicates that cancer cells have trouble repairing breaks in their DNA, making them vulnerable to certain therapies.
• The initial genetic makeup of the tumor: Analyzing the tumor’s genetic profile before treatment can help doctors identify cancers that are predisposed to losing the RB1 gene.

“This represents a major advance in understanding and predicting cancer behavior in response to treatment,” says Dr. Pedram Razavi, Physician-Scientist at MSK and lead author of the study.

The Role of BRCA2 Mutations

The study revealed a strong link between inherited mutations in the BRCA2 gene and the development of resistance. Patients with BRCA2 mutations were found to be more likely to acquire additional mutations in RB1. This suggests that individuals born with a BRCA2 mutation may not respond as well to CDK4/6 inhibitor-based therapy. The researchers likewise found that tumors with only one functional copy of the RB1 gene before starting treatment were at a significantly higher risk of completely losing the gene during therapy.

To understand the underlying mechanisms, the MSK team conducted laboratory experiments using patient-derived xenograft models from BRCA2-mutant breast cancers. These experiments confirmed that CDK4/6 inhibitors were less effective in tumors prone to losing the RB1 gene during treatment.

Shifting Treatment Strategies: The EvoPAR-Breast01 Trial

Based on these findings, a global Phase 3 clinical trial, EvoPAR-Breast01, is now underway. This trial is testing a new approach for patients with newly diagnosed, ER-positive, HRD-positive metastatic breast cancer. Instead of initiating treatment with CDK4/6 inhibitors, the trial will evaluate the effectiveness of therapies targeting HRD, specifically the PARP inhibitor saruparib combined with the hormonal therapy camizestrant.

The rationale behind this shift is that PARP inhibitors are particularly effective in tumors with DNA repair defects like HRD. The researchers hypothesize that by targeting HRD first, they can delay or even prevent the development of resistance to CDK4/6 inhibitors.

How HRD Drives Resistance

The study highlights how underlying DNA repair defects, particularly HRD, can independently increase the likelihood of acquiring RB1 alterations. Dr. Razavi explains that cancers don’t have an unlimited number of ways to evade treatment. they typically rely on a limited set of mechanisms determined by their genetic features. By predicting these mechanisms, clinicians hope to intercept resistance before it occurs.

Interestingly, the research also revealed that some tumors can develop “reversion mutations” that restore DNA repair function. Once HRD is reversed, these tumors may regain sensitivity to CDK4/6 inhibitors. This suggests that using PARP inhibitors early on may not only improve initial outcomes but also potentially restore responsiveness to CDK4/6 inhibitors later in the course of treatment.

A Broad Genomic Analysis

The MSK research involved a comprehensive analysis of data from over 5,800 breast cancer patients. This analysis examined how both inherited (germline) and acquired (somatic) genetic changes influence tumor growth and response to therapy. Key findings from this analysis include:

• Patients with inherited BRCA2 mutations are more likely to develop additional mutations in RB1.
• These patients generally experience poorer outcomes when treated with standard CDK4/6 inhibitor-based therapy.
• Tumors carrying only one copy of the RB1 gene before starting CDK4/6 inhibitor treatment are much more likely to develop complete RB1 loss.
• Underlying DNA repair defects – especially HRD – further drive the resistance mechanism.
• In preclinical models, PARP inhibitors demonstrated better outcomes than CDK4/6 inhibitors in tumors with HRD.

The Importance of Translational Research

This study is part of a larger effort at MSK to anticipate and counteract breast cancer treatment resistance. Dr. Sarat Chandarlapaty, a physician-scientist who co-led the study, emphasized the importance of integrating clinical observations with rigorous laboratory modeling. “The ability to test hypotheses generated from data in patient-derived models and engineered cell lines allows us to move beyond correlation and establish biological causality,” he said.

The rapid translation of these findings into a Phase 3 clinical trial underscores the strength of MSK’s research program and its commitment to improving patient care. Dr. Razavi noted that We see rare for translational data to be compelling enough to warrant a direct move into a Phase 3 study without earlier clinical evidence.

Looking Ahead

The EvoPAR-Breast01 trial represents a significant step towards personalized treatment for metastatic breast cancer. The researchers hope that by identifying high-risk tumors and tailoring treatment strategies accordingly, they can improve outcomes and extend the lives of patients with this challenging disease. The team also expressed gratitude to the thousands of patients who have participated in MSK’s translational research programs, emphasizing that their contributions were essential to making this work possible.